相关实验视频

Updated: Sep 12, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

在Nirsevimab预防的背景下,在西澳大利亚的呼吸道同位素病毒菌株进化和突变

Binit Lamichhane^1,2, Cara A Minney-Smith¹, Jake Gazeley¹

¹Department of Microbiology, PathWest Laboratory Medicine WA, Nedlands, Australia.

Open forum infectious diseases

|August 6, 2025

概括

尼尔西维玛能有效地预防婴儿的呼吸道同胞性病毒 (RSV),在2024年季节在西澳大利亚没有发现逃生突变. 持续监测对于保持这一重要的RSV预防工具的长期疗效至关重要.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
公共卫生公共卫生

背景情况:

尼尔塞维马布是一种长效单克隆抗体,用于预防婴儿和高危儿童的呼吸道同胞病毒 (RSV).
在西澳大利亚的2024年RSV季节,注射了超过23,000剂尼尔塞维马布.
尼尔塞维马布逃生变体的可能性对其持续的有效性提出了担忧.

研究的目的:

为了研究RSVF蛋白的nirsevimab结合部位的突变.
评估潜在的nirsevimab逃生变体的出现和传播.
分析临床和废水样本的RSV遗传多样性和耐药性突变.

主要方法:

382个临床和12个废水RSV样本的全基因组测序.
对RSV亚型,遗传多样性和尼尔塞维马布结合区域内的突变进行分析.
遗传学分析,以评估血统动态和潜在的变种的出现.

主要成果:

RSV-A是主要的亚型 (61.8%),其次是RSV-B (38.2%).
没有发现显著的血统转移或已知的高水平尼尔塞维马布耐药性突变.
发现了一种常见的RSV-B突变 (F:I206M:Q209R:S211N),但与降低nirsevimab疗效无关.
废水监测证实,珀斯大都会地区没有耐药突变.

结论:

在2024年RSV季节的临床或废水样本中没有发现nirsevimab逃逸突变.
基因组监测,包括基于废水的流行病学,对于监测RSV演变至关重要.
持续监测确保尼尔塞维马布在RSV预防方面的长期有效性.

关键词:

F 蛋白质 F 蛋白质这就是为什么RSV RSV.逃生变体的逃生变体突变是一种突变.没有自己的生活.废水是废水,废水就是废水.

更多相关视频

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

相关概念视频

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...